Pfizer's Obesity Therapy Could Be First Monthly GLP-1 Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Clinical Trial Results: Pfizer (PFE) reported mid-stage trial results for its obesity therapy berobenatide (PF’3944) at the 86th Scientific Sessions of the American Diabetes Association, indicating its potential to be the first approved monthly GLP-1 therapy, which could create a competitive edge in the market.
- Competitive Data: In the Phase 2b VESPER-1, 2, and 3 trials, berobenatide demonstrated continuous weight loss while maintaining a tolerable profile as patients transitioned from weekly to monthly dosing, highlighting its potential for long-term management of obesity-related conditions.
- Future Trial Plans: Pfizer intends to conduct up to 10 Phase 3 trials this year to further validate berobenatide's efficacy, particularly in the long-term management of overweight or obese adults, showcasing the company's commitment and confidence in the drug's market prospects.
- Market Context: Currently approved GLP-1 receptor agonists like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are available as weekly injectables, while the monthly dosing regimen of berobenatide may attract patients seeking more convenient treatment options, potentially increasing Pfizer's market share in obesity treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.690
Low
24.00
Averages
28.56
High
35.00
Current: 25.690
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Advances Berobenatide in Phase 2b Trials for Obesity Management
- Clinical Trial Results: Pfizer presented Phase 2b study results for berobenatide at the 86th Scientific Sessions of the American Diabetes Association, showing a nearly 16% non-placebo-adjusted weight loss at 32 weeks with a 2.4 mg weekly dose, indicating the drug's potential in obesity management.
- Future Research Plans: Pfizer plans to initiate 10 Phase 3 studies in 2026 targeting obesity and related comorbidities, such as knee osteoarthritis and obstructive sleep apnea, which will significantly bolster its market position in obesity treatment.
- Dosing Strategy: The Phase 2b studies demonstrated continuous weight loss across all selected doses while maintaining a tolerable profile during the transition from weekly to monthly dosing, laying a solid foundation for future clinical applications.
- Patient-Friendly Delivery: With an injection volume of only 0.5 mL, the drug offers a convenient administration experience, which may enhance patient adherence and lead to better long-term outcomes in obesity treatment.
See More
Pfizer's Obesity Therapy Could Be First Monthly GLP-1 Drug
- Clinical Trial Results: Pfizer (PFE) reported mid-stage trial results for its obesity therapy berobenatide (PF’3944) at the 86th Scientific Sessions of the American Diabetes Association, indicating its potential to be the first approved monthly GLP-1 therapy, which could create a competitive edge in the market.
- Competitive Data: In the Phase 2b VESPER-1, 2, and 3 trials, berobenatide demonstrated continuous weight loss while maintaining a tolerable profile as patients transitioned from weekly to monthly dosing, highlighting its potential for long-term management of obesity-related conditions.
- Future Trial Plans: Pfizer intends to conduct up to 10 Phase 3 trials this year to further validate berobenatide's efficacy, particularly in the long-term management of overweight or obese adults, showcasing the company's commitment and confidence in the drug's market prospects.
- Market Context: Currently approved GLP-1 receptor agonists like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are available as weekly injectables, while the monthly dosing regimen of berobenatide may attract patients seeking more convenient treatment options, potentially increasing Pfizer's market share in obesity treatment.
See More
Viatris Sales Trends Improve, Valuation Potential Rises
- Sales Recovery: Viatris reported a 3% year-over-year revenue increase and a 14% rise in adjusted earnings per share in Q1, indicating a rebound after years of declining revenue, showcasing the restoration of stable cash flow and profitability.
- Pipeline Development Opportunities: The company's focus on a non-opioid pain reliever, a potential lupus treatment, and a heart attack 'EpiPen' is expected to significantly drive long-term revenue growth, enhancing investor confidence and shareholder value.
- Cost Control Effectiveness: Strategic cost-cutting measures implemented post-review are projected to save the company $400 million by 2028, further improving profitability and exceeding market expectations, demonstrating enhanced operational efficiency.
- Strong Performance in China: Sales in the Greater China region rose 18% year-over-year, driven by an aging population and increased demand for cardiovascular drugs, indicating Viatris's strong competitive position and market adaptability in a rapidly growing market.
See More
Vaccination Policy Justifications Under Scrutiny
- Research Retractions and Investigations: Three scientific papers used by HHS Secretary Robert F. Kennedy Jr. are facing retractions or investigations due to serious methodological flaws, highlighting the fragility of the evidence supporting vaccination policy and potentially undermining public trust in vaccines.
- Health Risk Claims Undermined: The studies claimed vaccinated children face higher health risks, but with the retraction and ongoing investigations, the scientific basis for these claims is being questioned, which may lead policymakers to reconsider childhood immunization schedules.
- CDC Policy Changes Impact: The CDC previously cited one of these studies to alter its stance on vaccines and autism, sparking controversy; the retraction of this evidence may prompt the CDC to reassess its position on vaccine safety.
- Legal and Political Interplay: Kennedy's lawyer called for changes to the childhood immunization schedule before a federal vaccine advisory committee, relying on these controversial studies, reflecting the complex relationship between science and politics that could influence future vaccine policy decisions.
See More
Pfizer Partners with Chai Discovery for AI Treatment Development
- AI Platform Collaboration: Pfizer has signed an agreement with Chai Discovery to utilize its AI platform for discovering new treatments, indicating Pfizer's proactive approach in innovative drug development despite undisclosed financial details.
- Generative AI Technology: Chai's generative AI software can predict and reprogram interactions between molecules, enabling scientists to design biomolecules with specific functional properties, thereby enhancing Pfizer's research and development efficiency.
- Custom Model Access: Pfizer will gain access to the Chai-3 model along with a custom model tailored to Pfizer's proprietary data and workflows, which will help achieve greater precision and efficiency in drug development.
- Strategic Implications: By partnering with Chai, Pfizer not only strengthens its technological capabilities in biopharmaceuticals but also positions itself more favorably in future market competition, potentially driving long-term growth.
See More
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.96 and a high of $160.59, with the last trade at $152.25, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and potential investment opportunities.
See More
Pfizer Advances Berobenatide in Phase 2b Trials for Obesity Management
- Clinical Trial Results: Pfizer presented Phase 2b study results for berobenatide at the 86th Scientific Sessions of the American Diabetes Association, showing a nearly 16% non-placebo-adjusted weight loss at 32 weeks with a 2.4 mg weekly dose, indicating the drug's potential in obesity management.
- Future Research Plans: Pfizer plans to initiate 10 Phase 3 studies in 2026 targeting obesity and related comorbidities, such as knee osteoarthritis and obstructive sleep apnea, which will significantly bolster its market position in obesity treatment.
- Dosing Strategy: The Phase 2b studies demonstrated continuous weight loss across all selected doses while maintaining a tolerable profile during the transition from weekly to monthly dosing, laying a solid foundation for future clinical applications.
- Patient-Friendly Delivery: With an injection volume of only 0.5 mL, the drug offers a convenient administration experience, which may enhance patient adherence and lead to better long-term outcomes in obesity treatment.
See More
Pfizer's Obesity Therapy Could Be First Monthly GLP-1 Drug
- Clinical Trial Results: Pfizer (PFE) reported mid-stage trial results for its obesity therapy berobenatide (PF’3944) at the 86th Scientific Sessions of the American Diabetes Association, indicating its potential to be the first approved monthly GLP-1 therapy, which could create a competitive edge in the market.
- Competitive Data: In the Phase 2b VESPER-1, 2, and 3 trials, berobenatide demonstrated continuous weight loss while maintaining a tolerable profile as patients transitioned from weekly to monthly dosing, highlighting its potential for long-term management of obesity-related conditions.
- Future Trial Plans: Pfizer intends to conduct up to 10 Phase 3 trials this year to further validate berobenatide's efficacy, particularly in the long-term management of overweight or obese adults, showcasing the company's commitment and confidence in the drug's market prospects.
- Market Context: Currently approved GLP-1 receptor agonists like Novo Nordisk's Wegovy and Eli Lilly's Zepbound are available as weekly injectables, while the monthly dosing regimen of berobenatide may attract patients seeking more convenient treatment options, potentially increasing Pfizer's market share in obesity treatment.
See More
Viatris Sales Trends Improve, Valuation Potential Rises
- Sales Recovery: Viatris reported a 3% year-over-year revenue increase and a 14% rise in adjusted earnings per share in Q1, indicating a rebound after years of declining revenue, showcasing the restoration of stable cash flow and profitability.
- Pipeline Development Opportunities: The company's focus on a non-opioid pain reliever, a potential lupus treatment, and a heart attack 'EpiPen' is expected to significantly drive long-term revenue growth, enhancing investor confidence and shareholder value.
- Cost Control Effectiveness: Strategic cost-cutting measures implemented post-review are projected to save the company $400 million by 2028, further improving profitability and exceeding market expectations, demonstrating enhanced operational efficiency.
- Strong Performance in China: Sales in the Greater China region rose 18% year-over-year, driven by an aging population and increased demand for cardiovascular drugs, indicating Viatris's strong competitive position and market adaptability in a rapidly growing market.
See More
Vaccination Policy Justifications Under Scrutiny
- Research Retractions and Investigations: Three scientific papers used by HHS Secretary Robert F. Kennedy Jr. are facing retractions or investigations due to serious methodological flaws, highlighting the fragility of the evidence supporting vaccination policy and potentially undermining public trust in vaccines.
- Health Risk Claims Undermined: The studies claimed vaccinated children face higher health risks, but with the retraction and ongoing investigations, the scientific basis for these claims is being questioned, which may lead policymakers to reconsider childhood immunization schedules.
- CDC Policy Changes Impact: The CDC previously cited one of these studies to alter its stance on vaccines and autism, sparking controversy; the retraction of this evidence may prompt the CDC to reassess its position on vaccine safety.
- Legal and Political Interplay: Kennedy's lawyer called for changes to the childhood immunization schedule before a federal vaccine advisory committee, relying on these controversial studies, reflecting the complex relationship between science and politics that could influence future vaccine policy decisions.
See More
Pfizer Partners with Chai Discovery for AI Treatment Development
- AI Platform Collaboration: Pfizer has signed an agreement with Chai Discovery to utilize its AI platform for discovering new treatments, indicating Pfizer's proactive approach in innovative drug development despite undisclosed financial details.
- Generative AI Technology: Chai's generative AI software can predict and reprogram interactions between molecules, enabling scientists to design biomolecules with specific functional properties, thereby enhancing Pfizer's research and development efficiency.
- Custom Model Access: Pfizer will gain access to the Chai-3 model along with a custom model tailored to Pfizer's proprietary data and workflows, which will help achieve greater precision and efficiency in drug development.
- Strategic Implications: By partnering with Chai, Pfizer not only strengthens its technological capabilities in biopharmaceuticals but also positions itself more favorably in future market competition, potentially driving long-term growth.
See More
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.96 and a high of $160.59, with the last trade at $152.25, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and timing for investments.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to stay informed about market dynamics and potential investment opportunities.
See More
